Indian Journal of Pharmacology Home 

EDUCATIONAL FORUM
[View FULLTEXT] [Download PDF]
Year : 2015  |  Volume : 47  |  Issue : 5  |  Page : 479--483

TNFerade, an innovative cancer immunotherapeutic

Arunava Kali 
 Department of Microbiology, Mahatma Gandhi Medical College and Research Institute, Puducherry, India

Correspondence Address:
Dr. Arunava Kali
Department of Microbiology, Mahatma Gandhi Medical College and Research Institute, Puducherry
India

Tumor necrosis factor-α (TNF-α) is a chemokine with effective tumoricidal properties. However, severe systemic toxicity limits its use of as anticancer agent. TNFerade is a novel replication deficient adenovector based gene therapy, which enables the radiation inducible translation of human TNF-α gene specifically in cancer cells. When injected intratumorally, it has least systemic distribution. Consequently, it lacks TNF-α related systemic toxicity. Evidence suggests that it has superior tumoricidal activity and tolerability with minimum adverse effects. It has demonstrated its beneficial role in the treatment of a variety of cancers in terms of improving the disease free and overall survival, delaying tumor progression, and inducing tumor regression when used with concurrent radiotherapy or chemotherapy.


How to cite this article:
Kali A. TNFerade, an innovative cancer immunotherapeutic.Indian J Pharmacol 2015;47:479-483


How to cite this URL:
Kali A. TNFerade, an innovative cancer immunotherapeutic. Indian J Pharmacol [serial online] 2015 [cited 2021 Oct 18 ];47:479-483
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2015;volume=47;issue=5;spage=479;epage=483;aulast=Kali;type=0